- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05868915
HV-101 for Patients With Advanced Solid Tumors
A Phase I/II Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of HV-101 Injection for the Patients With Recurrent or Metastatic Solid Tumors
Background:
Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. TIL therapy has shown strong efficacy for the treatment of solid tumors, and has achieved high objective response rates in multiple cancers.
Objective:
To evaluate the safety and efficacy of HV-101 for the treatment of advanced solid tumors.
Eligibility:
Adults aging 18-75 with advanced solid tumors
Design:
- Patients will undergo screening tests, including imaging procedures, heart and lung tests, and lab tests.
- Freshly resected patient tumors were dissected by the surgeon.
- TIL cells were isolated from the patient's tumor tissue in the laboratory, then cultured in vitro, activated and expanded.
- HV-101 will be re-infused into the patient.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Qibin Song, Doctor
- Phone Number: 13517281931
- Email: qibinsong@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Recruiting
- Renmin Hospital of Wuhan University
-
Contact:
- Qibin Song, PhD
- Phone Number: 13517281931
- Email: qibinsong@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be able to understand and sign the Informed of Consent Document. Be willing to follow the procedure and protocol of the clinical trial.
- Age ≥ 18 years and ≤ 75 years.
- Expected survival time > 3 months.
- ECOG score 0-1.
- At least one lesion that could undergo surgery or biopsy to obtain tumor tissue for TIL preparation
- At least 1 measurable lesion (according to RECIST v1.1).
- Metastatic or recurrent solid tumors confirmed by histopathology. Refractory to standard treatment evaluated by radiological assessment.
Hematology should at least meet the following criteria:
- Absolute neutrophil count (ANC) ≥ 1.5× 109/L;
- Platelet (PLT) ≥ 75× 109/L;
- Hemoglobin (HGB) ≥ 90 g/L.
Liver and kidney function are normal:
- Serum creatinine (Cr) ≤ 1.5 times of upper limit of normal (ULN) or creatine clearance ≥ 60 ml/min;
- Serum Alanine aminotransferase (ALT) or/and Aspartate aminotransferase (AST) ≤ 2.5 times of ULN;
- Total bilirubin (TBIL) ≤ 1.5 times of ULN.
Blood coagulation function is normal:
- Prothrombin time (PT) ≤ 1.5 ULN;
- International Normalized Ratio (INR) ≤ 1.5 ULN;
- or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 ULN.
- Women of childbearing potential should be ascetic or take contraception since the signing of ICF to 24 weeks or later after the last administration of drug.
Exclusion Criteria:
- Under pregnancy or lactation, or positive based on blood pregnancy test.
- Severe allergic to related ingredients in the clinical trial.
- Received any other investigational treatment within 28 days before the administration of HV-101.
- History of other known malignant tumors within the previous 5 years.
- Primary central nerve system (CNS) cancer, or Participants with CNS metastasis after localized treatment.
- Participants with any active autoimmune disease, a history of autoimmune disease, or a history or syndrome requiring treatment with systemic steroids or immunosuppressive drugs.
- Immunodeficiency including HIV positive, acquired or primary immunodeficiency.
- Participants with ≥ grade 3 thromboembolic events within 6 months or under thrombolysis treatment.
- Participants with hereditary or acquired hemorrhagic disease.
- Participants with clinical cardiovascular disease or symptoms
- Participants with active infection.
- Participants with active pulmonary tuberculosis infection.
- Participants with positive hepatitis B surface antigen or positive hepatitis B core antibody or positive hepatitis C virus antibody.
- Treponema pallidum antibody positive.
- Participants received major surgery or under severe injury within 28 days before HV-101 infusion.
- Participants who received live vaccine or attenuated live vaccine 28 days before HV-101 infusion.
- Participants who have drug addiction history, alcoholism, or drug users.
- Participants who received cell therapy before enrollment.
- Participants who have contraindications to the treatment of IL-2 injection.
- Participants not suitable for the clinical trial evaluated by the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HV-101
Participants with Advanced Solid Tumors Interventions: Biological: HV-101 Drug: IL-2 Drug: Fludarabine Drug: Cyclophosphamide |
Biological: HV-101 HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification. Drug: IL-2 Following cell infusion, the patient receives intravenous IL-2. Drug: Fludarabine Part of the non-myeloablative lymphocyte-depleting preparative regimen. Drug: Cyclophosphamide Part of the non-myeloablative lymphocyte-depleting preparative regimen. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of HV-101
Time Frame: Day 0 - Day 730
|
The safety of HV-101 will be assessed based on the totality of dose-limiting toxicity (DLT) and adverse event (AE) data collected during this phase.
|
Day 0 - Day 730
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Day 0 - Day 730
|
To evaluate the proportion of participants who have a confirmed partial response (PR) and complete response (CR) per RECIST v1.1 as assessed by the investigator.
|
Day 0 - Day 730
|
Duration of Response (DOR)
Time Frame: Day 0 - Day 730
|
To evaluate the duration from the time that criteria are met for CR or PR per RECIST v1.1 as assessed by the investigator until disease progression or death due to any cause.
|
Day 0 - Day 730
|
Disease Control Rate (DCR)
Time Frame: Day 0 - Day 730
|
To evaluate the percentage of participants with a best overall confirmed response of CR or PR at any time plus stable disease (SD) per RECIST v1.1 as assessed by the investigator.
|
Day 0 - Day 730
|
Progression free survival (PFS)
Time Frame: Day 0 - Day 730
|
To evaluate the time from the date of HV-101 infusion until disease progression per RECIST v1.1 as assessed by the investigator or death due to any cause.
|
Day 0 - Day 730
|
Overall survival (OS)
Time Frame: Day 0 - Day 730
|
To evaluate the time from the date of HV-101 infusion to death due to any cause.
|
Day 0 - Day 730
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CV101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
Clinical Trials on HV-101
-
Vrije Universiteit BrusselOmron Healthcare Co., Ltd.CompletedChronic Low Back Pain | Movement Evoked PainBelgium
-
University of British ColumbiaUnknownPain | Periodontal Disease | Wound Healing | Tissue Adhesive | Dental Scaling | Oral Surgical ProceduresCanada
-
Vrije Universiteit BrusselCompleted
-
Hull University Teaching Hospitals NHS TrustCompletedHeart FailureUnited Kingdom
-
DMG Dental Material Gesellschaft mbHUniversity of Coimbra; University Arthur Sá Earp NetoNot yet recruitingDental CariesBrazil, Portugal
-
Stryker OrthopaedicsCompletedArthritis Knee | Aseptic Loosening
-
Mathilde Peters, DMD, PhDDentsply International; Mott Children's Health CenterCompleted
-
Michael DunbarCompleted
-
Maastricht University Medical CenterMaastricht UniversityUnknownTranscatheter Aortic Valve Replacement | Transcatheter Aortic Valve Implantation | Left Bundle Branch BlockNetherlands
-
Seoul National University HospitalCompletedBreast CancerKorea, Republic of